NCT06955169 - Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2030

Conditions

Intracranial Meningioma

Interventions

DRUG

[177Lu]Lu-DOTATATE

The treatment regimen consists of 4 (+2 optional) administrations of \[177Lu\]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).

OTHER

Standard of Care treatments

Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Local SOC therapy with one of the following agents: bevacizumab, everolimus, hydroxyurea, or sunitinib.